 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The company will do operations &amp; management of newly constructed hospital facilities for 30 years.

Shalby gains on amendment agreement for hospital building in Mumbai

A bullish outlook on the Nifty will be confirmed above the 19,850 mark. Further resistance levels are 20,000 and 20,200

Hot Stocks | Bet on KEI Industries, Shalby, DCX Systems for 12-16% return in short term

Shalby  Consolidated September 2023 Net Sales at Rs 237.98 crore, up 17.93% Y-o-Y

Apart from capacity expansion, Shalby is also exploring opportunities in the home care sector

Shalby zooms 10% ahead of meeting with Swiss investor: Stake deal on the cards?

Shares of Shalby have rallied 19.56% in four consecutive sessions.The stock hit a 52-week high of Rs 225.55 today. The stock hit a 52-week low of Rs 114.35 on 28 March 2023.The stock had outperformed the market over the past one month, advancing 18.26% as against Sensexs 2.17% decrease.The scrip had outperformed the market in past three months, jumping 60.11% as against 5.28% increase in Sensex.The counter had also outperformed the market in past one year, soaring 81.69% as against Sensexs 10.99% surge.On the technical front, the stocks daily RSI (relative strength index) stood at 73.499. The RSI oscillates between zero and 100. Traditionally, the RSI is considered overbought when above 70 and oversold when below 30.On the daily chart, the stock was trading above its 50 day, 100-day and 200-day simple moving average (SMA) placed at 181.29, 160.98 and 151.59, respectively. These levels will act as crucial support zones in near term.Shalby is a company engaged in healthcare delivery space and listed with bourses in India. The company operates as a chain of multispecialty hospitals across India. The business of the company is to offer tertiary and quaternary healthcare services to patients in various areas of specialization such as orthopedics, complex joint replacements, cardiology, neurology, oncology, renal transplantations etc.The companys consolidated net profit rose 3.6% to Rs 20.83 crore on 16.8% increase in net sales to Rs 235.49 crore in Q1 FY24 over Q1 FY23.

Shalby spurts 20% in four days; hits 52-week high

Shalby  Consolidated June 2023 Net Sales at Rs 235.49 crore, up 16.76% Y-o-Y

Shalby  Standalone June 2023 Net Sales at Rs 211.12 crore, up 19.21% Y-o-Y

ICICI Direct is bullish on Shalby recommended buy rating on the stock with a target price of Rs 220 in its research report dated July 14, 2023.

Buy Shalby; target of Rs 220: ICICI Direct

The enthusiasm is reflected in the 30 percent rally in share price of Shalby over the past month. This was on the back of Shalby being is a market leader in arthroplasty procedure, while diversification and strong growth outlook on the implant business has also added legs to the rally.

Shalby hits 52-week high; diversification, strong outlook for implant business fuels rally

Shalby  Consolidated March 2023 Net Sales at Rs 198.98 crore, up 22.4% Y-o-Y

Shalby Ltd. engages in the operation of hospitals and outpatient clinics. It provides medical diagnostic services in the field of orthopedics, cardiology, general medicine, dental, neurosurgery, oncology, renal transplantation and general surgery. The company was founded by Vikram I. Shah in March 1994 and is headquartered in Ahmedabad, India.

Market Cap	31.39B
Volume (M)	648,417.00
52-Wk High	327.35
52-Wk Low	115.00

SHALBY.NSE Shalby Ltd.

About

Feed

News

Fundamentals